Exagen Posts Record Quarterly Revenue Growth with Higher Test Pricing, Losses Persist
Exagen delivered record quarterly revenue driven by increased average pricing on its autoimmune diagnostic tests. Net loss widened year-over-year as the company sustained elevated sales and R&D spending to fuel future growth initiatives.
1. Record Revenue and Pricing Gains
Exagen achieved its highest quarterly revenue to date as average price per test rose significantly alongside growing test volumes. The pricing increase on core autoimmune panels contributed the majority of the year-over-year revenue lift while new customer adoption expanded its diagnostic reach.
2. Continued Net Losses and Investment
Despite top-line strength, Exagen’s net loss expanded as the company maintained high levels of sales, general and administrative, and research-and-development expenses. Management emphasized ongoing investments in commercial infrastructure and product innovation to support long-term profitability and market penetration.